Interactions of mesenchymal stromal/stem cells and immune cells following MSC-based therapeutic approaches in rheumatoid arthritis

• Published in: Cellular immunology Vol. 393-394; p. 104771
• Main Authors: Dehnavi, Sajad, Sadeghi, Mahvash, Tavakol Afshari, Jalil, Mohammadi, Mojgan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-11-2023
• Subjects: Adaptive immunity; Animals; Arthritis, Rheumatoid; Humans; Immune cell; Immunomodulation; Innate immunity; Killer Cells, Natural - metabolism; Macrophages - metabolism; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mesenchymal stromal/stem cell; Rheumatoid arthritis; T-Lymphocytes - metabolism; RANKL; M-CSF; PT; BCA-1; RANTES; HO; ISCT MSC; UCW; ICAM-1; anti-CCP; Breg; IRF-4; GM-CSF; IDO; Tfh; TSG-6; AIA; iNOS; CIA; STAT-3; BAFF; Tfr; AD; IL; Immunomodulation; HGF; PBMC; RA; MMP; RF; Rheumatoid arthritis; Men; ROS; BLC; AFA; HLA; Mesenchymal stromal/stem cell; CRP; NO; FDA; Bcl-6; COX-2; FL; NSAID; SDF-1; Innate immunity; BM; FLS; ROR-γt; MIP-1α; PD-L1; NLRP3; MSC; IBMIR; APRIL; PGE2; ESR; Treg; DMARD; Adaptive immunity; ECM; BATF; Mcl-1; TF; APC; TNF-α; NAG; UCB; NK cell; Bax; TGF-β1; CTL; NET; PL; Immune cell; DC; MHC-II
• ISSN: 0008-8749; 1090-2163
• DOI: 10.1016/j.cellimm.2023.104771

•Rheumatoid arthritis (RA) is a chronic autoimmune disorder involving joints and synovium due to dysregulated immune responses.•Mesenchymal stem cells (MSCs) are multipotent stromal cells capable of self-renewal, differentiation, and inducing tissue regeneration and emerged as a promising therapeutic candidate for various inflammatory diseases.•MSC therapy can administered as an alternative candidate for refractory RA patients following interaction with various innate and adaptive immune cells to suppress deregulated humoral immunity and regulate imbalanced cell responses
Rheumatoid arthritis (RA) is considered to be a degenerative and progressive autoimmune disorder. Although several medicinal regimens are used to treat RA, potential adverse events such as metabolic disorders and increased risk of infection, as well as drug resistance in some patients, make it essential to find an effective and safe therapeutic approach. Mesenchymal stromal/stem cells (MSCs) are a group of non-hematopoietic stromal cells with immunomodulatory and inhibitory potential. These cells exert their regulatory properties through direct cell-to-cell interactions and paracrine effects on various immune and non-immune cells. As conventional therapeutic approaches for RA are limited due to their side effects, and some patients became refractory to the treatment, MSCs are considered as a promising alternative treatment for RA. In this review, we introduced various experimental and clinical studies conducted to evaluate the therapeutic effects of MSCs on animal models of arthritis and RA patients. Then, possible modulatory and suppressive effects of MSCs on different innate and adaptive immune cells, including dendritic cells, neutrophils, macrophages, natural killer cells, B lymphocytes, and various subtypes of T cells, were categorized and summarized. Finally, limitations and future considerations for the efficient application of MSCs as a therapeutic approach in RA patients were presented.